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Abstract 
Objectives: Opiorphin is a pentapeptide isolated from human saliva that suppresses pain from 
chemically induced inflammation and acute physical pain. Burning mouth syndrome (BMS) is 
a chronic condition of a burning sensation in the mouth, where no underlying dental or medical 
cause can be identified. We aimed to measure the level of opiorphin in whole unstimulated 
(UWS) and stimulated (SWS) saliva of patients with BMS. 
Materials and methods: Originally developed and validated LC-MS/MS method was used for 
opiorphin quantification. 
Samples were obtained from 29 BMS patients and 29 age and sex-matched controls. 
Results: The average concentration of opiorphin in UWS and SWS in the BMS group was 8.13 
± 6.45 and 5.82 ± 3.59 ng/ml, respectively. Opiorphin in BMS patients’ UWS was significantly 
higher, compared to the control group (t = 2.5898; p = 0.0122). SWS opiorphin levels were 
higher, but not significantly, in BMS patients than in controls. 
Conclusions: Our results indicate that higher quantities of salivary opiorphin in BMS may be 
a consequence of chronic pain, but we cannot exclude that they occur as a result of emotional 
and behavioral imbalances possibly associated with BMS. To our knowledge, this is the first 
original article measuring opiorphin in a pain disorder. 
Clinical relevance: Opiorphin may be a measurable biomarker for chronic pain, which could 
help in objectifying otherwise exclusively a subjective experience. Increased opiorphin could 
serve as a universal objective indicator of painful conditions. 
Since opiorphin may also reflect emotional and socio-relational imbalances occurring with 
BMS, it could as well represent a biomarker for BMS. Knowledge on opiorphin’s involvement 
in pain pathways could contribute to developing new clinical diagnostic methods for BMS. 




Opiorphin is an endogenous pentapeptide isolated in 2006 from human saliva [1]. It was 
described as a mature product of the proline-rich, lacrimal 1 (PROL1) protein and shown that 
it inhibits enkephalin-inactivating ectopeptidases, human neutral ecto-endopeptidase (hNEP), 
and human ectoaminopeptidase (hAP-N), thus resulting in extended analgesic activity of 
enkephalins. Initial research on rats showed that it suppresses pain sensation for both chemical-
induced and acute mechanical pain as efficiently as morphine but without causing drug 
tolerance and with fewer morphine-associated side effects [1, 2]. It was previously observed 
that central administration of opiorphin induced an antidepressant-like effect by activation of 
μ and δ opioid receptors [3–5], as well as showed to affect colonic motility [6, 7]. Apart from 
saliva, opiorphin has been detected in plasma, cerebrospinal fluid, urine, tears, semen, and 
breast milk [8, 9]. To our knowledge, limited data are available on its levels, as wells as age 
and gender distribution. Only few papers have been published on opiorphin quantification [9, 
10]. 
Being involved in pain pathways, opiorphin could potentially represent a valuable biomarker 
for different types of physiological disorders. Because of its abundance in the oral milieu, we 
hypothesize that it might affect pain regionally, especially in common idiopathic orofacial pain 
conditions, such as “burning mouth syndrome” (BMS). 
“BMS is a debilitating chronic condition of a burning sensation in the mouth, where no 
underlying dental or medical cause can be identified and no oral signs can be found” [11, 12]. 
The discomfort may affect the tongue, gums, lips, inside of the cheeks, roof of the mouth, or 
the whole mouth and is often accompanied by dry mouth and altered taste sensation [11–13]. 
Although BMS can affect anyone, it occurs most commonly in middle-aged or older women. 
It is estimated that it affects up to 14%postmenopausal women and about 1% of general 
population with a male-to-female ratio being 1:7 [12, 14]. Till this day, the etiology of BMS is 
poorly understood. 
Various published treatment attempts generally lack evidence of real long-term efficiency [12]. 
For the past several decades, literature has been pointing towards the involvement of neural 
mechanisms in the etiology of BMS [15–18] and the current research suggests the same [19]. 
Therefore, we believe that levels of salivary opiorphin may present a biomarker for this 
condition. 
Differences in saliva composition have previously been observed in BMS patients, compared 
to healthy individuals. Nagler and Hershkovich have suggested oral neuropathy or neurologic 
transduction interruption background induced by compositional saliva alterations in patients 
with oral sensory complaints, such as BMS [17]. Additionally, Granot and Nagler have 
corroborated the altered salivary composition, i.e., elevated Na, K, Cl, Ca, IgA, and amylase 
concentrations in patients with oral sensory complaints, including BMS patients [18]. Both 
studies suggested a local neuropathic process underlying the patients’ complaints; however, 
central involvement could also partake in the onset and perpetuation of burning symptoms [15, 
19]. 
Opiorphin, because of its involvement in pain pathways, could present a salivary marker for 
the local neuropathic condition, such as BMS. 
Aim of the study was to investigate levels of salivary opiorphin in patients with BMS in 
unstimulated whole saliva (UWS) and stimulated whole saliva (SWS) and to compare the 
results with the healthy control group. Different opiorphin levels than in control subjects would 
confirm the neuropathic background in the development of the BMS. We had hypothesized 
that we may encounter lower opiorphin levels in BMS patients, which would implicate that a 
relative scarcity of this potent pain suppressor could, in certain individuals, lead to development 
of BMS. 
Materials and methods 
Patients and controls 
Saliva samples were obtained from 29 patients with BMS (24 females and 5 males, mean age 
67.45 ± 9.44 years, range 43–84) treated at the Department of Oral Medicine, Zagreb School 
of Dental Medicine, and 29 age- and sex-matched control subjects (20 females and 9 males, 
mean age 67.31 ± 12.66 years, range 38–89) recruited from patients of the Department of 
Endodontics and Restorative Dentistry, Zagreb School of Dental Medicine from February to 
May 2014. A statistical power analysis was performed for sample size estimation, based on 
data from our pilot study [20, 21]. Based on the results of that study, the average concentration 
of opiorphin in saliva of healthy volunteers was 8.5 ± 5.0 ng/ml. 
There was no significant difference in opiorphin level in female vs. male subjects (9.4 ± 5.4 
vs. 7.2 ± 4.6 ng/ml). Since the difference between female and male was 2.2 ng/ml, it would be 
reasonable to assume that differences between study and control group should be at least twice 
as large in order to verify differences between the study groups. With an alpha = 0.05 and 
power = 0.90, the projected sample size needed with this variance (GPower Win 3.1.9.2. 
(Heinrich-Heine-Universität, Düsseldorf, Germany)) was approximately N = 26 for the 
between group comparison. Thus, our proposed sample size of 29 should be adequate for the 
main objective of this study especially since there is no attrition possible in this type of study. 
Diagnosis of BMS was established by experienced oral medicine specialists, in accordance 
with the presence of typical symptoms: daily and symmetrical burning pain sensation of the 
oral mucosa, lasting for at least 3 months, with constant or increasing intensity, that endures 
more than 2 h during the day and improves during eating or drinking, having no interference 
with sleep, and unaccompanied by any dental, oral, or medical clinical signs [11, 12]. Subjects 
abstained from food and beverages at least for 8 h and did not brush their teeth prior to sample 
collection. Saliva sampling took place in the morning, between 8 and 10 a.m. Periodontal health 
was assessed by papillary bleeding index (PBI) on Ramfjord index teeth (nos. 3, 9, 12, 19, 25, 
and 28). When a subject was missing a Ramfjord index tooth, a tooth closest to it was assessed. 
BMS group inclusion criteria are as follows: no systemic pain, no oral or dental clinical signs, 
PBI 0 or 1, regular medication use if under therapy, and well-controlled systemic diseases or 
conditions. Control group inclusion criteria are no oral/dental or systemic pain, seen by dentist 
for regular checkups (at least once a year), saliva samples taken only if dental procedures were 
not required, PBI 0 or 1, regular medication use if under therapy, and well-controlled systemic 
diseases or conditions. Prior to sample collection, the subjects’ medical history was recorded. 
In order to eliminate other possible influences on opiorphin levels and ensure that groups are 
well matched, BMS and control subjects were compared according to their medical history, 
drug consumption, and oral clinical findings. Subjects’ medications were indexed by the 
Anatomical Therapeutical Chemical Classification System (ATC) [22], while the subjects’ 
systemic conditions were indexed by the International Statistical Classification of Diseases and 
Related Health Problems (ICD-10) [23]. 
The experimental procedures were conducted in accordance with ethical standards of the 
Declaration of Helsinki and approved by the Ethics Committee of the School of Dental 
Medicine on 9 December 2010.Written informed consent was obtained from all participants. 
The method, sample collection, and manipulation were previously described in detail and 
validated by our group [21]. Briefly, an original sensitive, specific, and reliable liquid 
chromatography-mass spectrometry method was utilized for quantification of salivary 
opiorphin. 
One saliva sample contained approximately 2 ml of saliva (2 ml UWS + 2 ml SWS per patient). 
Saliva was obtained from mouth floor with a vacuum saliva collector that delivered it into a 
pre-weighed graduated tube containing 300 μl of trifluoroacetic acid (TFA) kept on ice. 
Salivation was induced by 1 % ascorbic acid solution by applying it onto the antero-dorso-
lateral surfaces of the tongue and vestibular mucosa using a cotton swab for 60 s, followed by 
a mouth rinse using the rest of the ascorbic acid solution for 30 s. Afterwards, the samples were 
vortexed and left on ice for 20 min and afterwards centrifuged (20,000×g, 30 min, at 4 °C). 
Supernatant (800 μl) was placed into a separate tube and then freeze-dried. The residue was 
dissolved in 200 μl of 0.1%formic acid (FA) in water, and an aliquot of 30 μl was analyzed by 
LC-MS/MS (Agilent Technologies 1200 series HPLC system, Agilent Technologies Inc., Palo 
Alto, CA, USA). 
Electrospray positive ionization-mass spectrometric multiple reaction monitoring 
(ESI+/MRM) experiments were used for quantifying opiorphin. Agilent MassHunter software 
was used for data processing. Compound-specific MRM was performed with ESI-MS/MS in 
order to ensure the quantification accuracy. 
Quantification of opiorphin was performed using the ESIMS positive ion mode, which 
produced a stable doubly charged [M+2H]2+ ion at m/z 347 with optimal fragmentor voltage 
at 135 V. Since the transition m/z 347/120 showed best intra- and inter-day precision, the lowest 
limit of detection, and the lowest susceptibility to the matrix effect, fragment ion m/z 120 was 
chosen as a quantifier ion, while ions m/z 175 and 268 as qualifier ions [21]. The limit of 
detection of opiorphin in human saliva was previously defined [21], 0.028, 0.031, and 0.057 
ng for m/z 120, 175, and 268, respectively, and the lower limit of quantification was 2.0, 3.0, 
and 4.0 ng/ml for m/z 120, 175, and 268, respectively. 
This case-control study was designed in compliance with “The Strengthening the Reporting of 
Observational Studies in Epidemiology” checklist. 
Statistical analysis 
Predictive Analytics Software (PASW) for Windows version 17.0 (SPSS Inc., Chicago, IL, 
USA) was used. Numeric data were described using the arithmetic mean, standard deviation, 
median, interquartile range, range, and minimal and maximal value. Qualitative data was 
described by frequency and percentage. Quantitative data distribution was tested by 
Kolmogorov-Smirnov test. Statistical significance of differences in mean values was tested 
using Student’s t test due to the normal distribution of data. When routed for a nonparametric 
test, Mann-Whitney U test was used. Multiple linear regression model was used to test the 
influence of drug consumption and systemic conditions on opiorphin levels. The confidence 
interval was ignored when the test was not significant. The level of significance was set at 5 
%. 
Results 
There was no statistically significant difference neither in age (t test, t = 0.048, p = 0.962) nor 
in gender (χ2 test, χ2 = 1.507, p = 0.220) between the two groups. 
Relation between systemic conditions, drug consumption, and the opiorphin level was 
investigated. Table 1 shows the subjects’ medical diseases and conditions indexed by ICD-10. 
None of the subjects with gastritis had developed gastroesophageal reflux disease. Subjects’ 
drug consumption, indexed by ATC, is shown in Table 2. No statistical difference was found 
for those relations (data not shown, available on request). The influence of smoking on the 
opiorphin level could not be calculated due to the small number of smokers included in the 
research (four smokers (13.33 %) in the control group and two (6.90 %) in the BMS group). 
Since none of the subjects had refused to participate or quit during the experiment, and all 
information requested was provided, we report no missing data. 
Table 3 shows opiorphin levels (mean, range, median, and SD) in UWS and SWS in BMS 
subjects and controls (ng/ml). 
Table 4 shows the opiorphin levels testing results within and between groups in UWS and 
SWS. Figure 1 describes the relationship of opiorphin levels within and between groups in 
UWS and SWS. Comparison between groups showed statistically significant increase of 
opiorphin levels in UWS of BMS patients, as compared to age- and sex-matched controls. SWS 
was also increased in BMS group, as compared to controls, but it was not statistically 













Table 1. Subjects' medical history indexed by International Statistical Classification of Diseases 
and Related Health Problems (ICD-10) 
Diseases and conditions  
BMS group (N 
(%)) 




Healthy*  4 (13.79) 8 (27.59) 12 (20.69) 
Essential hypertension (I10) 6 (20.70) 8 (27.59) 14 (24.14) 
Atherosclerosis (I70)  4 (13.79) 4 (13.79) 8 (13.79) 
Phlebitis and thrombophlebitis (I80) 2 (6.90) 1 (3.45) 3 (5.17) 
Angina pectoris (I20) 3 (10.34) 2 (6.90) 5 (8.62) 
Varicose veins of lower extremities (I-83)  2 (6.90) 4 (13.79) 6 (10.34) 
Iron deficiency anemia (D50) 1 (3.45) 0 (0.00) 1 (1.72) 
Gastritis and duodenitis (K29) 11 (37.93) 5 (17.24) 16 (27.59) 
Simple chronic bronchitis (J41.0) 1 (3.45) 0 (0.00) 1 (1.72) 
Calculus of kidney and ureter (N20) 1 (3.45) 2 (6.90) 3 (5.17) 
Osteoporosis without pathological fracture 
(M81) 
3 (10.34) 0 (0.00) 3 (5.17) 
Depression (F32) 5 (17.24) 2 (6.90) 7 (12.10) 
Type 2 diabetes mellitus (E11) 2 (6.90) 3 (10.34) 5 (8.62) 
Hypothyroidism (E03) 4 (13.79) 2 (6.90) 6 (10.34) 
Epilepsy (G40) 1 (3.45) 1 (3.45) 2 (3.44) 
Asthma (J45) 0 (0.00) 1 (3.45) 1 (1.72) 
Abbreviations: BMS: Burning mouth syndrome  
* no systemic illness  
 
Table 2. Subject's drug consumption (medications indexed by the Anatomical Therapeutical 







None 7 (24.14) 8 (27.59) 15 (25.86) 
Calcium channel blockers (C08) 4 (13.79) 6 (20.70) 10 (17.24) 
Proton pump inhibitors (A02BC) 7 (24.14) 3 (10.34) 10 (17.24) 
Ibuprofen (C01EB16) 4 (13.79) 1 (3.45) 5 (8.62) 
Acetylsalicylic acid (B01AC30) 4 (13.79) 8 (27.59) 12 (20.69) 
Benzodiazepine derivatives (N05CD) 2 (6.90) 4 (13.79) 6 (10.34) 
Sex hormones and modulators of the genital system 
(G03) 
0 (0.00) 1 (3.45) 1 (1.72) 
Angiotensin II antagonists, plain (C09C) 1 (3.45) 2 (6.90) 3 (5.17) 
Beta blocking agents (C07) 3 (10.34) 6 (20.70) 9 (15.51) 
ACE inhibitors, plain (C09A) 7 (24.14) 6 (20.70) 13 (22.41) 
HMG- CoA reductase inhibitors (C10AA) 4 (13.79) 5 (17.24) 9 (15.51) 
Opioids (N02A) 1 (3.45) 0 (0.00) 1 (1.72) 
Levothyroxine sodium (H03AA01) 4 (13.79) 2 (6.90) 6 (10.34) 
Blood glucose lowering drugs, excluding insulins 
(A10B) 
2 (6.90) 3 (10.34) 5 (8.62) 
Antihistamines for systemic use (R06) 2 (6.90) 0 (0.00) 2 (3.44) 
Anti-asthmatics (R03) 0 (0.00) 1 (3.45) 1 (1.72) 
Aminosalicylic acid and derivatives (J04AA) 1 (3.45) 0 (0.00) 1 (1.72) 
Antiinflammatory and antirheumatic products, non-
steroids (M01A) 
1 (3.45) 1 (3.45) 2 (3.44) 
Antiepileptics (N03AX) 1 (3.45) 1 (3.45) 2 (3.44) 
Isosorbide mononitrate (C01DA14) 3 (10.34) 2 (6.90) 5 (8.62) 
Warfarin (B01AA03) 2 (6.90) 3 (10.34) 5 (8.62) 
Drugs acting on serotonin receptors (A03AE) 1 (3.45) 0 (0.00) 1 (1.72) 
Clopidogrel (B01AC04) 0 (0.00) 1 (3.45) 1 (1.72) 
Bisphosphonates, combinations (M05BB) 2 (6.90) 0 (0.00) 2 (3.44) 
Abbreviations: BMS: Burning mouth syndrome 
 
Table 3. Opiorphin values (in ng/ml) for the BMS and the control group in UWS and SWS 
 
 BMS Control 
 UWS SWS UWS SWS 
Mean 8.129 5.819 5.017 4.992 
Standard deviation 6.445 3.594 2.585 3.212 
Min. value 1.811 1.049 2.033 1.618 
Max. value 25.612 14.425 10.724 15.322 
Median 5.951 5.096 4.592 4.265 
95% confidence interval 5.677 / 10.580 4.452 / 7.186 4.034 / 6.001 3.771 / 6.214 
Interquartile range 7.364 2.969 3.780 3.084 
Abbreviations: BMS: Burning mouth syndrome; UWS: Unstimulated whole saliva; SWS: 
Stimulated whole saliva 
 
Table 4: Comparison of opiorphin levels between groups 
 t df p SED* 
BMS – Control group (UWS) 2.413 56 0.0191** 1.289 
BMS - Control group (SWS) 0.9239 56 0.3595 0.895 
BMS group (UWS – SWS) 1.6857 56 0.0974 1.370 
Control group (UWS – SWS) 0.0327 56 0.9741 0.766 
Abbreviations: BMS: Burning mouth syndrome; UWS: Unstimulated whole saliva; SWS: 






Figure 1: Opiorphin mean value (with standard errors) comparison between the burning mouth syndrome group (BMS) and 






Literature reports a clear predisposition of BMS patients to gender and age with women being 
2.5–7-fold more commonly affected than men [13, 24, 25]. Furthermore, around 90 % of 
women affected are in menopause [26]. Mean age of the BMS group investigated was 67.5, 
67.3 of the control group, and 82.8 % of all subjects were female. 
 
A possible limitation to this research is the early morning saliva sampling. It is known that 
BMS symptoms are usually less prominent in the morning hours [27]. However, morning saliva 
sampling has the advantage of excluding possible confounders, e.g., food and beverage 
influence on saliva and opiorphin secretion. A study on the circadian rhythm of salivary 
opiorphin is needed, as information on its concentration span remains unknown. 
 
We performed a multiple linear regression analysis to see if levels of opiorphin were affected 
by systemic conditions or drug consumption. We found no correlation between drug 
consumption and systemic conditions and the level of opiorphin. To assess the influence of a 
certain condition or medication on the level of salivary opiorphin, research with a larger sample 
might be needed, as current sample size might represent a limitation of the study. Subjects were 
primarily matched for age and gender in order to minimize the influence of those variables on 
the measured variable, opiorphin levels. Subsequent data analysis revealed that we also 
obtained good matching of systemic conditions and medications between groups. 
 
One of the first papers on opiorphin was a one by Wisner et al. [1], where the authors described 
opiorphin as a physiological pain suppressant and a mood-related modulator. As mentioned in 
the “Introduction”, opiorphin activates endogenous opioid-dependent transmission, inhibiting 
the chemical and mechanical evoked pain behavior, with the effectiveness similar to morphine 
[1]. The zinc metal ectopeptidases located on the cell surface control the activity of neural and 
hormonal mediators, e.g., inactivation of the enkephalins and similar molecules, which regulate 
the analgesic mechanisms and emotional responses and states. Opiorphin was proven as a dual 
inhibitor of the enkephalin degrading hNEP and hAP-N, enabling the prolonged effect of 
enkephalins. Furthermore, it was proven to display analgesic activity in vitro, thereby 
suggesting therapeutic implications [1]. 
In a study by Dufour et al. [8], the levels of opiorphin were measured in different body fluids 
(blood, tears, saliva, urine, and lactating milk). Interestingly, difference was found between 
male and female subjects in the urinary opiorphin levels. The authors suggested that the 
opiorphin secretion is influenced by gender; however, the statistical difference was not 
observed in the bloodstream opiorphin levels. High heterogeneity in the bloodstream of female 
subjects observed by Dufour et al. was explained by the hormonal influence, even though the 
menstrual cycle phase had not been registered or the levels of androgens measured. 
The function of opiorphin in the body fluids is yet to be discovered and is still based on 
speculations. However, it is clear that it exerts organ-specific functions through 
neuroendocrine, paracrine, and/or autocrine and/or exocrine mechanisms [8]. High level of 
opiorphin was observed in a study by Rougeot in a female volunteer undergoing thyroid 
hormone replacement therapy (basal conditions = 1072 ng/ml; stimulated conditions = 1637 
ng/ml) [9]. Six of our subjects were undergoing a levothyroxine therapy but showed no such 
deviations. However, opiorphin level of one female subject from the control group patient was 
very high (15.32 ng/ml), possibly because she was undergoing estradiol, estriol, and 
norethisterone acetate replacement therapy. Medications can present possible confounders, as 
their influence on levels of opiorphin is unknown. 
We have noticed a consistent decrease in the opiorphin level after saliva stimulation. This is in 
accordance with our previous study [21]. Gene expression and levels of SMR1 protein were 
found to be different among rats’ salivary glands, being highest in the submandibular gland 
and slightly lower in parotid gland [28]. This could suggest an unequal expression 
of human genes related to SMR1 in different types of salivary glands. Our result could support 
this hypothesis as levels of opiorphin in UWS, secreted mainly by the submandibular 
glands, were higher than in SWS, which is secreted mainly by the parotid glands. We believe 
that the reason for this difference, apart from the possible unequal gene expression, could also 
be a dilution due to the increased salivary flow, resulting in a more serous saliva produced by 
parotid serous acinar cells. 
In contrast, in two ELISA-based studies [9, 9], a significant increase in opiorphin levels was 
described in both genders after chemically induced salivation. In addition to that, their average 
values of opiorphin were six to ten times higher than ours. As described in a study by Brkljačić 
and her group [21], higher values measured in the ELISA-based studies could be an outcome 
of the interferences that affect the antibody binding specificity, in this case immature products, 
translational peptides, derived from the PROL1 protein. The translational 
peptides, due to their different mass, are invisible to the MS detector, which could not be the 
case with the ELISA antibodies. However, Al Saffar et al. obtained similar opiorphin levels to 
ours in an ELISA-based study [10]. Had we encountered lower opiorphin levels in BMS, we 
could consider that a lack of opiorphin had a role in the neural mechanisms leading to onset of 
BMS, due to loss of inherent pain controlling mechanism. Increased opiorphin levels in BMS 
patients could reflect the adaptive reaction consequent to chronic pain. Al Saffar et al. showed 
the difference in the levels of opiorphin before and after administrating local anesthesia [10], 
supporting the thesis that the elevated opiorphin levels are a result of painful stimuli. 
Furthermore, by comparing the elevated concentrations in our study and in the study 
by Al Saffar et al. [10], we can assume that greater level of opiorphin is to be observed in acute 
pain stimuli, i.e., needle penetration and voluminous tissue expansion, compared to the 
chronic pain stimuli, i.e., in BMS. It is therefore possible that opiorphin levels depend on the 
intensity of pain. A study on the correlation between pain intensity and opiorphin levels could 
provide us with a potential objective biomarker for pain. 
Another plausible explanation for increased opiorphin levels in BMS patients lies in its 
involvement in other enkephalin-mediated adaptation processes beyond nociception [3, 5]. 
These include emotion-related behaviors, stress-induced hyperalgesia, anxiety, and depression, 
which are common in BMS patients [13, 14]. This implies that opiorphin could also be a 
biomarker for BMS. For that matter, the limitation of this study is the lack of structured and 
validated psychological and emotional evaluation of the subjects. Our subjects have only self-
reported depression and their use of antidepressive medications, which could be biased. Had 
we recorded psychosocial and behavioral characteristics of our subjects, such data, if different 
between two groups, could have provided us with evidence of psychological aspects around 
BMS and thus would have also justified the increase in opiorphin levels. Higher vasoreactivity 
in BMS patients was reported by Heckmann et al. in a study on oral mucosal blood flow in 
BMS patients [29]. It has been proven that opiorphin has cardiovascular effects mediated 
through the renin-angiotensin system, as it rises the blood pressure and pulse when injected 
intravenously [30–32]. Curiously, BMS compatible symptoms were previously associated with 
antihypertensive drugs that act upon the angiotensin-renin system, angiotensin-converting 
enzyme inhibitors, and angiotensin II receptor blockers or antagonists [33]. 
Theories on opiorphin’s pathways, which might be of future interest, involve its possible 
implication in neuroendocrine axes. The UWS we collected originated mainly from the 
submandibular glands which, together with the cervical superior ganglia, form the cervical 
sympathetic trunk submandibular gland (CST-SMG) axis [34]. This “neuroendocrine axis” has 
barely been investigated in humans [35]. However, it is known that the rat homologue of 
opiorphin, sialorphin [1], is a product of this axis. Sialorphin is generated from the N-terminus 
of the submandibular rat-1 protein (SMR1), a prohormone and an end component of the axis 
[36]. SMR1 protein is encoded by the Vcsa1 gene, hormonally regulated by androgens [28, 36, 
37]. Expression of opiorphin genes in humans may be similarly regulated [36]. Etiology of the 
BMS has still not been defined, but some recent papers observed the levels of hormones and a 
possiblerelation of neuroendocrine disbalance and BMS [38, 39]. Levels of estrogen, 
progestones, and androgens decrease following menopause [40] and, as mentioned, the 
majority of BMS patients are menopausal and postmenopausal women. Therefore, we suggest 
a relationship between disbalanced androgen regulation in menopausal women, BMS, and 
opiorphin. A study on the topic is needed to confirm this hypothesis. Studies on differences in 
gene expression in salivary glands due to age and gender may help us understand predominance 
of menopausal and postmenopausal women in the BMS etiology. In a study by Srivastava et 
al., human parotid glands were compared among 32 otherwise healthy male and female subjects 
between 19 and 85 years of age [41]. Different gene expression was found in 787 gene probe 
sets. In 59%of probe sets, higher expression was identified in females and 29 % of alterations 
were due to aging. Furthermore, most of the differences were related to the genes linked to X 
and Y chromosome and immune response pathways [41]. Those findings on gender specificity 
of salivary genes expression and the influence of aging also fit in the puzzle of the 
“neuroendocrine regulation–BMS–salivary 
Opiorphin” triangle. However, the influence of aging on the PROL1 gene expression 
responsible for opiorphin remains unclear. Studies on PROL1 expression in BMS patients 
would surely reveal more information about the BMS etiology. 
In summary, our results opened new topics on opiorphin and BMS and provided 
encouragement for further studies on the relationship between opiorphin levels and different 
types of physiological disorders. Opiorphin could present a measurable biomarker for chronic 
pain, which could help in objectifying patients’ subjective experience. We used a sensitive and 
reliable LC-ESI-MS/MS method to determine the level of opiorphin in our subjects. 
Statistically significant increase of opiorphin in unstimulated saliva of BMS patients, compared 
to control group, could be a response to a chronic painful condition, but it could also be result 
psychological and socio-relational disturbances within BMS. To test the latter, 
we would need to assess psychological condition of BMS patients and controls in correlation 
to salivary opiorphin levels. 
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